Japanese company profile · 4519

Chugai Pharmaceutical Co., Ltd.

Official English company name published by the issuer.

Original Japanese company name: 中外製薬株式会社

Name follows the issuer's official English company information. English company name source

FY2025 · fiscal year ended December 2025Latest filing date: 2026-03-25

What does this company do?

What does this company do?

In its FY2025 public filing, Chugai Pharmaceutical Co., Ltd. reports Pharmaceuticals. The page shows business-level revenue and profit where the source disclosures support comparison.

Chugai Pharmaceutical Co., Ltd.'s largest reported business by revenue in FY2025 was Pharmaceuticals.

The business with the highest reported segment profit in FY2025 was Pharmaceuticals.

FY2025 · fiscal year ended December 2025 · View original filing ↗ The source document may be in Japanese.

Reported company-wide figures

Company revenue
¥1.26T ↗
FY2025 · fiscal year ended December 2025
Operating profit
¥598.83B ↗
FY2025 · fiscal year ended December 2025
Comparable margin
47.6% ↗
FY2025 · fiscal year ended December 2025

IFRS · Consolidated company-wide

Company profile

Company profile

Identity

Securities code
4519
EDINET code
E00932
Corporate number
5011501002900
Listing status
Listed
Industry (EDINET filer classification)
Pharmaceuticals

Location and fiscal year

Headquarters
東京都北区 · As filed in Japanese
Fiscal year end
12month
Latest fiscal year
FY2025
Accounting standard
IFRS
P16 data snapshot
2026-11-07

Company size

Employees (consolidated)
7,872 people (FY2025)
Employees (non-consolidated)
5,104 people (FY2025)
Capital stock
JPY 73.2 billion (FY2025)

Official information

Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab

Business structure

How does it make money?

Revenue leader and profit leader

Pharmaceuticals

FY2025 · fiscal year ended December 2025 · Business Segment revenue Segment profit (loss)
BusinessSegment revenueShare of company salesSegment profit (loss)Margin
Pharmaceuticals¥1.26T ↗—¥598.83B ↗47.6%

All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.

Company revenue

Company-wide trend

Company revenue

IFRS · Consolidated
  1. FY202179.3¥999.76B
  2. FY2022100.0¥1.26T
  3. FY202388.2¥1.11T
  4. FY202492.9¥1.17T
  5. FY202599.8¥1.26T

Company operating profit

IFRS · Consolidated
  1. FY202170.5¥421.9B
  2. FY202289.1¥533.31B
  3. FY202373.3¥439.17B
  4. FY202490.5¥542B
  5. FY2025100.0¥598.83B

Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.

Reported Segment revenue by business over time

Reported Segment revenue by business over time

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Pharmaceuticals¥999.76B¥1.26T¥1.11T¥1.17T¥1.26T

All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.

What is growing?

What is growing?

Business revenue growth

This describes a reported period; it is not a forecast.

What has changed?

What has changed?

A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.

Source

Company profile

These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.

  • Growth49
    Position among all companies with available values in the fixed reference data.FY2021→FY2025
  • Profitability100
    Position among all companies with available values in the fixed reference data.FY2025
  • Business concentration—
    No comparable data
  • Business change—
    No comparable data
  • Cash generation—
    No comparable data
  • Growth persistence43
    Peer-position scoreFY2021→FY2022, FY2022→FY2023, FY2023→FY2024, FY2024→FY2025

Next

Ask about this company

Source

Public filing

FY2025 · fiscal year ended December 2025

The source document may be in Japanese.

Filing ID: S100XTBJ

View original filing ↗

根拠となる資料